Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Depreciation & Amortization (CF) (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 10.95% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Dec 2025, up 0.88% year-over-year, with the annual reading at $4.7 million for FY2025, 0.88% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $1.2 million at 4D Molecular Therapeutics, down from $1.3 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $1.3 million in Q3 2025, with the low at $370000.0 in Q2 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $873850.0, with a median of $1.0 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 160.0% in 2022, then fell 10.4% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $390000.0 in 2021, then surged by 160.0% to $1.0 million in 2022, then increased by 8.68% to $1.1 million in 2023, then fell by 0.54% to $1.1 million in 2024, then increased by 10.95% to $1.2 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $1.2 million, $1.3 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.